Alzheimer’s drug shows promise but needs more study for safety, researchers say
11/30/22
from The Washington Post,
11/29/22:
The drug, lecanemab, is highly anticipated because it moderately slows progression of a disease without many treatments
More From The Washington Post (subscription required):
